Abvc Biopharma (ABVC) Depreciation & Amortization (CF) (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Depreciation & Amortization (CF) came in at $5783.0 in Q1 2026, down 17.63% YoY from $7021.0 in Q1 2025, and little changed on a QoQ basis from $5791.0 in Q4 2025.
Abvc Biopharma (ABVC) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $5783.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 17.63% year-over-year to $5783.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43601.0 (down 26.56% YoY) and the FY2025 annual result came in at $25330.0, down 20.91% from the prior year.
- Depreciation & Amortization (CF) was little changed at $5783.0 in Q1 2026, from $5791.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $28627.0 in Q3 2024 to a low of $1286.0 in Q1 2024.
- A 5-year average of $9211.2 and a median of $6697.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 80.19% — and 2025, when it jumped 445.96%.
- Tracing ABVC's Depreciation & Amortization (CF) over 5 years: stood at $6435.0 in 2022, then advanced by 17.82% to $7582.0 in 2023, then jumped by 37.43% to $10420.0 in 2024, then sank by 44.42% to $5791.0 in 2025, then fell by 0.14% to $5783.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $5783.0 (Q1 2026), $5791.0 (Q4 2025), and $25330.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12,299.00 |
| Jun 30, 2026 | 12,299.00 |
| Mar 31, 2026 | 5,783.00 |
| Mar 31, 2026 | 5,783.00 |
| Dec 31, 2025 | 5,791.00 |
| Dec 31, 2025 | 5,791.00 |
| Sep 30, 2025 | 25,330.00 |
| Sep 30, 2025 | 25,330.00 |
| Jun 30, 2025 | 6,697.00 |
| Jun 30, 2025 | 6,697.00 |
| Mar 31, 2025 | 7,021.00 |
| Mar 31, 2025 | 7,021.00 |
| Dec 31, 2024 | 10,420.00 |
| Dec 31, 2024 | 10,420.00 |
| Sep 30, 2024 | 28,627.00 |
| Sep 30, 2024 | 28,627.00 |
| Jun 30, 2024 | 13,305.00 |
| Jun 30, 2024 | 13,305.00 |
| Mar 31, 2024 | 1,286.00 |
| Mar 31, 2024 | 1,286.00 |